CORTEVA, INC.

(CTVA)
  Report
Delayed Nyse  -  04:03 2022-08-09 pm EDT
59.72 USD   +1.07%
08:02aBerenberg Bank Adjusts Corteva's Price Target to $66 From $58, Maintains Buy Rating
MT
07:57aRBC Raises Price Target on Corteva to $72 From $67, Citing 'Continued Robust Demand,' Strategic Review; Outperform Kept
MT
05:15aNORTH AMERICAN MORNING BRIEFING : Stocks to -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Corteva : Agriscience 2Q 2022 Earnings Conference Call Presentation

08/04/2022 | 05:43pm EDT

2Q 2022 Earnings Conference Call

August 5, 2022

Safe Harbor Regarding Forward-Looking Statements

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance ("ESG") targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to successfully develop and commercialize Corteva's pipeline; (ii) failure to obtain or maintain the necessary regulatory approvals for some of Corteva's products; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva's industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) failure to comply with competition and anti-trust laws; (x) competitor's establishment of an intermediary platform for distribution of Corteva's products; (xi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xiii) effect of volatility in Corteva's input costs; (xiv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xv) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xvi) increases in pension and other post-employment benefit plan funding obligations; (xvii) risks related to environmental litigation and the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xviii) risks related to Corteva's global operations; (xix) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xx) capital markets sentiment towards ESG matters; (xxi) risks related to COVID-19; (xxii) Corteva's ability to recruit and retain key personnel; (xxiii) Corteva's intellectual property rights or defend against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) Corteva's dependence on intellectual property cross-license agreements; (xxvi) other risks related to the Separation from DowDuPont; and (xxvii) risks related to the Russia and Ukraine military conflict.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.

2

A Reminder About Non-GAAP Financial Measures

Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating EBITDA margin, operating earnings (loss) per share, and base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided on slides 27 - 36 of this presentation.

Corteva is not able to reconcile its forward-lookingnon-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as Significant Items, without unreasonable effort. For Significant Items reported in the periods presented, refer to slide 29. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-yearramp-up period of Enlist E3TM, Corteva is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform after the completion of the ramp-up. Additionally, in connection with the Company's shift to a global business unit model, the Company has assessed its business priorities and operational structure to maximize the customer experience and deliver on growth and earnings potential. As a result of this assessment, the company has committed to restructuring actions that, combined with the impact of the company's separate announcement to withdraw from Russia and stop production and business activities ("Russia Exit") (collectively the "2022 Restructuring Actions"), have resulted in expected total pre-tax restructuring and other charges of approximately $350 million to $420 million. The restructuring actions associated with these charges are expected to be substantially complete in 2023.

Organic sales is defined as price and volume and excludes currency and portfolio impacts. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) benefits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings (loss) per share are defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Base income tax rate is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses), non-operating benefits (costs), amortization of intangibles (existing as of the Separation), mark-to-market gains (loss) on certain foreign currency contracts not designated as hedges, and significant items.

The Company also uses Free Cash Flow as non-GAAP measure to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash from operating activities, less capital expenditures. We believe that Free Cash Flow provides investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and our ability to service our indebtedness, pay dividends (when declared), make share repurchases, and meet our ongoing cash needs for our operations.

3

CEO Messages

Strong 1H Performance

  • Double digit organic(1) revenue growth reflects strong global demand
  • Volume, price and cost controls contributing to ~130 basis points of Operating EBITDA margin(1) expansion

Progress on Completed comprehensive strategic portfolio reviews

Strategic

Prioritizing core markets and crops to optimize resource allocation and

Framework

drive long-term value creation

Raising FY

Net sales $17.2B - $17.5B, 11% growth vPY at mid-point

Operating EBITDA(1) $2.95B - $3.10B, 17% growth vPY at mid-point

Guidance(2)

Increased dividend ~7%, Expect ~$1B in share repurchases for FY 2022

Technology and Strong Execution Driving Growth

  1. Organic sales growth, Operating EBITDA, and Operating EBITDA Margin are non-GAAP measures. See slide 3 for further discussion and reconciliations starting on slide 27.

(2) Guidance does not contemplate any extreme weather events, operational disruptions, significant changes in customers' demand or ability to pay, or further acceleration of currency and inflation impacts resulting from

4

global economic conditions.

Strategy Review Translating to Specific Actions

Key Strategic Choices

  1. Portfolio simplification
    • Identified core markets and crops - focus on growth, margin, and competitive positioning
    • Exiting non-strategic geographies and select product lines
    • Preserving ~95% and ~99% of current Net Sales and Operating EBITDA(1), respectively
  2. Fit for purpose cost structure and support model
    • Resource allocation to drive performance in both global business units
    • Right sizing and optimizing cost structure to enable greater agility and operating leverage

3 Restructuring actions

  • Pre-taxrestructuring and other charges of approximately $400M expected through 2Q23
  • Significant run-rate savings will contribute to margin expansion

Simplification and Focus to Accelerate Performance

(1) Operating EBITDA is a non-GAAP measure. See slide 3 for further discussion and reconciliations starting on slide 27.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Corteva Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 21:36:03 UTC.


© Publicnow 2022
All news about CORTEVA, INC.
08:02aBerenberg Bank Adjusts Corteva's Price Target to $66 From $58, Maintains Buy Rating
MT
07:57aRBC Raises Price Target on Corteva to $72 From $67, Citing 'Continued Robust Demand,' S..
MT
05:15aNORTH AMERICAN MORNING BRIEFING : Stocks to -2-
DJ
08/08Mizuho Securities Raises Corteva's Price Target to $69 From $68, Maintains Buy Rating
MT
08/08Deutsche Bank Adjusts Corteva Price Target to $68 From $72, Maintains Buy Rating
MT
08/08Citigroup Adjusts Corteva's Price Target to $69 From $63, Reiterates Buy Rating
MT
08/08Roth Capital Adjusts Corteva's Price Target to $74 From $67, Reiterates Buy Rating
MT
08/08JPMorgan Upgrades Corteva to Overweight From Neutral, Adjusts Price Target to $63 From ..
MT
08/05CORTEVA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
08/05UBS Adjusts Corteva Price Target to $66 From $64, Maintains Buy Rating
MT
More news
Analyst Recommendations on CORTEVA, INC.
More recommendations
Financials (USD)
Sales 2022 17 212 M - -
Net income 2022 1 592 M - -
Net cash 2022 2 434 M - -
P/E ratio 2022 27,1x
Yield 2022 0,95%
Capitalization 42 915 M 42 915 M -
EV / Sales 2022 2,35x
EV / Sales 2023 2,18x
Nbr of Employees 21 000
Free-Float 99,4%
Chart CORTEVA, INC.
Duration : Period :
Corteva, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORTEVA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 59,72 $
Average target price 65,95 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Charles V. Magro Chief Executive Officer & Director
David John Anderson Chief Financial Officer & Executive Vice President
Gregory R. Page Non-Executive Chairman
Sam Eathington Chief Technology Officer & Senior Vice President
Marcos Marinho Lutz Independent Director
Sector and Competitors